血液灌流联合血液透析对尿毒症并发症疗效观察  

EFFECT OF HEMOPERFUSION COMBINED WITH HEMODIALYSIS FOR PATIENTS WITH UREMIA

作　　者：王世明[1] 

机构地区：[1]临沂市人民医院肾内科,山东临沂276000

出　　处：《牡丹江医学院学报》2007年第6期36-38,共3页Journal of Mudanjiang Medical University

摘　　要：目的:观察血液灌流联合血液透析对尿毒症并发症的临床疗效。方法:选取维持性透析尿毒症患者30例,采用血液灌流联合血液透析治疗,每月2次,共治疗16周,观察治疗前后患者皮肤瘙痒、骨痛、不安腿综合征、睡眠及自主感觉等临床症状变化,检测肾功能、电解质、甲状旁腺素(PTH)、b2微球蛋白(b2-MG)。结果:多数患者皮肤瘙痒、骨痛、不安腿综合征症状减轻,睡眠改善,自主感觉良好;血PTH从(321.9±301.2)ng/L降至(176.5±143.5)ng/L、血b2-MG从(910.3±32.8)nmol/L降至(284.6±20.2)nmol/L,治疗前后比较有显著性差异(p<0.05),且无严重的不良反应。结论:血液灌流联合血液透析可显著降低尿毒症患者血中PTH、b2-MG等中分子物质,对患者的皮肤瘙痒、骨痛、不安腿综合征等症状疗效显著,并且改善睡眠及自主感觉。Objective：To observe the effect of hemoperfusion combined with hemodialysis for patients with uremia. Methods：Thirty uremia patients were treated with bemoperfusion combined with hemodialysis twice a month. The total observation period was 16 weeks. The blood urea nitrogen, creatinine, electrolyte, parathyroid hormone （FFH）, b2 - miocroglobulin （b2- MG）and clinical manifestation were observed before and after the treatment. Results：The clinical manifestations were improved in majority of the patients. The PTH decreased from（321.9 ± 301.2）ng/L to （176. 5 ± 143.5 ） ng/L and b2 - MG decreased from （910.3 ± 32.8 ） nmol/L to （ 284.6 ± 20.2 ） nmol/L with a significant difference from pre -treatment（ p 〈0.05 ）. No serious sideeffect was observed. Condision ：The treatment of hemoperfusion combined with hemodialysis can effectively eliminate the middle molecular substance（ such as FTH,b2 -MG ） and improve some of clinical manifestations in uremic patients effectively.

关 键 词：血液灌流 血液透析 尿毒症 

分 类 号：R57[医药卫生—消化系统]